Trial · NCT03110770
Results by group329
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 329
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / None | 26 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | Swelling / None | 25 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | Swelling / None | 23 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / None | 1059 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | Swelling / None | 1124 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / Mild | 4 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | Swelling / Mild | 5 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | Swelling / Mild | 6 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / Mild | 82 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | Swelling / Mild | 22 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / Moderate | 0 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | Swelling / Moderate | 0 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | Swelling / Moderate | 1 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / Moderate | 12 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | Swelling / Moderate | 2 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / Severe | 0 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | Swelling / Severe | 0 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | Swelling / Severe | 0 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | Swelling / Severe | 0 | Participants | |
| Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After Each Product Administration (Part A and Part B) | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | Swelling / Severe | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03110770/results?page=2